IMMPACT:Initiative for Cell Mortality Programme Assessment.

Cell Death, Apoptosis, Oxidative stress, Caspase, BCL2

Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV

purofied native dsDNA

ABSTRACT
While immunoglobulin G (IgG) antibodies against double-stranded (ds) DNA are serological markers of systemic lupus erythematosus (SLE), not all anti-DNA (anti-DNA) antibodies are positively damaged. It has been suggested that anti-DNA-induced renal damage may be associated with differences in the fine specificity of antibodies. In an effort to gain insight into their fine binding properties, we investigated the cross-reactivity of two human lupus anti-dsDNA monoclonal IgGs (B3 to RH14) to the recently described PolIV. These autoantibodies have distinct pathogenic properties in mice with severe combined immunodeficiency (SCID). Although both antibodies cause proteinuria, only RH14 induces the early histological features of lupus nephritis.

Both RH14 and B3 bound PolIV; however, they showed a significant difference in their reactivity to the PolIV – dsDNA complex. Although RH14 showed significant activity to the complex, the binding of B3 to PolIV complexed with dsDNA was almost abolished. In addition, there was a significant difference in the way lupus is recognized by naked dsDNA and which is presented on PolIV. Although 67% of lupus sera bound to bare dsDNA, ≈ 90% of these sera (93% calf thymus DNA; 90% synthetic oligonucleotide) responded to the complex when the dsDNA was presented on PolIV. Thus, anti-dsDNA IgG, which is likely to exist in lupus patients, can be distinguished between those that recognize dsDNA in the context of PolIV and those that do not. This difference in binding ability can help differentiate those dsDNA antibodies that are more pathogenic.

Key words: autoantibodies, autoimmunity, human, lupus, PolIV

 

ADDITIONAL INFORMATION
Product Name Purified Native dsDNA, Calf Thymus, ELISA/Antigen grade
Supplier name Alpha Diagnostic
Size 1 mg
Form Powder
Datasheet URL View Datasheet
Product Type Antibody Purification
Publications Publication List
purofied native dsDNA
purofied native dsDNA

Anti-dsDNA antibodies anti-ssDNA antibodies

2.1. Anti-DNA antibodies and their correlation with the pathogenesis of SLE
Systemic lupus erythematosus (SLE) is a chronic, potentially fatal autoimmune disease characterized by exacerbations and remissions with a variety of clinical manifestations affecting multiple organ systems, including the skin, kidneys, joints, cardiovascular and nervous systems. A hallmark of systemic lupus erythematosus is the production of a number of IgG and IgM autoantibodies directed against one or more nuclear components, the most common of which are double-stranded (ds) DNA and / or single-stranded (ss) DNA. Both anti-ssDNA and anti-dsDNA are involved in disease development and have been eluted from the kidneys of experimental mouse models and patients with SLE [17]. Clinicians consider anti-dsDNA autoantibodies to be relatively disease-specific, while anti-ssDNA is non-specific.

The reason for the difference in disease specificity is that for antibodies against dsDNA, the sensitivity of the test is 60%, while for these antibodies the variability is 30-70% [18]. The level of anti-DNA antibodies varies in the plasma of different patients with SLE, with high levels of anti-ssDNA and / or anti-dsDNA antibodies being associated with flare-ups of symptoms [4, 5]. As a result, the level of anti-DNA antibodies in the serum of patients is used to monitor the activity and progression of the disease [4-6].

The exact mechanisms leading to the production of anti-DNA antibodies remain unknown. Subgroups of B-cell producers vary according to different authors [19-21]. In addition, the mechanisms of pathogenicity of anti-DNA antibodies and immune complexes in SLE are controversial. Part of the pathogenicity may be due to the direct hydrolytic and cytotoxic activity of anti-DNA antibodies on cells of various tissues and organs affected by the disease [18]. Pathogenic anti-DNA antibodies are able to interact at the tissue level with alpha actinin in the renal glomeruli.

At the cellular level, antibodies have been shown to react with various cell surface proteins (eg, Myosin 1), presumably to allow them to penetrate the cell [22–25]. Upon entering the cell, the anti-DNA antibody is translocated to the nucleus, where it binds to the DNA and subsequently hydrolyzes it. An alternative mechanism by which an anti-DNA antibody may lead to autoimmune disease is its interaction with cell death receptors, which initiates a proapoptotic signal that apparently leads to tumor cell death in vitro and possibly lupus B-cell death in vivo [12, 15 , 26, 27]. Although this phenomenon is due in part to caspase activation, the possible link between DNA hydrolysis and programmed cell death, as well as the underlying mechanisms in SLE, are not clearly understood [12]. The differences between natural and pathogenic anti-DNA autoantibodies are summarized in Figure 1.

Human Preferentially Expressed Antigen In Melanoma (PRAME) Protein
20-abx068652
  • EUR 878.40
  • EUR 343.20
  • EUR 2749.20
  • EUR 1045.20
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Preferentially Expressed Antigen In Melanoma (PRAME) Protein
20-abx068653
  • EUR 878.40
  • EUR 343.20
  • EUR 2749.20
  • EUR 1045.20
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Melanoma antigen preferentially expressed in tumors (PRAME)
1-CSB-YP018603HU
  • EUR 516.00
  • EUR 280.80
  • EUR 1809.60
  • EUR 770.40
  • EUR 1210.80
  • EUR 349.20
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Melanoma antigen preferentially expressed in tumors(PRAME) expressed in Yeast

Human Melanoma antigen preferentially expressed in tumors (PRAME)
1-CSB-EP018603HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Melanoma antigen preferentially expressed in tumors(PRAME) expressed in E.coli

Preferentially Expressed Antigen In Melanoma (PRAME) Antibody Pair
20-abx370326
  • EUR 2097.60
  • EUR 1345.20
  • 10 × 96 tests
  • 5 × 96 tests

Human Preferentially Expressed Antigen In Melanoma (PRAME) CLIA Kit
20-abx495430
  • EUR 9567.60
  • EUR 5095.20
  • EUR 1177.20
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Melanoma Antigen Preferentially Expressed In Tumors (PRAME) Antibody
20-abx004948
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Human Striated muscle preferentially expressed protein kinase (SPEG)
1-CSB-EP022529HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Striated muscle preferentially expressed protein kinase(SPEG),partial expressed in E.coli

Melanoma Antigen Preferentially Expressed In Tumors (PRAME) Antibody
abx236746-100ug 100 ug
EUR 661.2

Melanoma Antigen Preferentially Expressed In Tumors (MAPE) Antibody
abx032957-400ul 400 ul
EUR 627.6

Melanoma Antigen Preferentially Expressed In Tumors (MAPE) Antibody
abx032957-80l 80 µl
EUR 343.2

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
DLR-PRAME-Hu-48T 48T
EUR 620.4
Description: A sandwich quantitative ELISA assay kit for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in samples from tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
DLR-PRAME-Hu-96T 96T
EUR 807.6
Description: A sandwich quantitative ELISA assay kit for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in samples from tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
20-abx152813
  • EUR 8853.60
  • EUR 4719.60
  • EUR 1093.20
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RD-PRAME-Hu-48Tests 48 Tests
EUR 625.2

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RD-PRAME-Hu-96Tests 96 Tests
EUR 867.6

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RDR-PRAME-Hu-48Tests 48 Tests
EUR 652.8

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RDR-PRAME-Hu-96Tests 96 Tests
EUR 907.2

Human Preferentially Expressed Antigen In Melanoma ELISA Kit (PRAME)
RK02126 96 Tests
EUR 625.2

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
SEH323Hu-10x96wellstestplate 10x96-wells test plate
EUR 5677.8
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
SEH323Hu-1x48wellstestplate 1x48-wells test plate
EUR 572.76
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
SEH323Hu-1x96wellstestplate 1x96-wells test plate
EUR 766.8
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
SEH323Hu-5x96wellstestplate 5x96-wells test plate
EUR 3090.6
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
4-SEH323Hu
  • EUR 5738.40
  • EUR 3031.20
  • EUR 768.00
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Preferentially Expressed Antigen In Melanoma (PRAME) in samples from tissue homogenates, cell lysates, cell culture supernates and other biological fluids with no significant corss-reactivity with analogues from other species.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RD-PRAME-Hu-48T 48T
EUR 452.7
Description: tissue homogenates, cell lysates, cell culture supernatants and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RD-PRAME-Hu-96T 96T
EUR 646.7
Description: tissue homogenates, cell lysates, cell culture supernatants and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RDR-PRAME-Hu-48T 48T
EUR 475.34
Description: tissue homogenates, cell lysates, cell culture supernatants and other biological fluids.

Human Preferentially Expressed Antigen In Melanoma (PRAME) ELISA Kit
RDR-PRAME-Hu-96T 96T
EUR 679.04
Description: tissue homogenates, cell lysates, cell culture supernatants and other biological fluids.